• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: ALCON RESEARCH, LTD. - HUNTINGTON MONARCH IOL DELIVERY SYSTEM, CARTRIDGE; FOLDERS AND INJECTORS, INTRAOCULAR LENS (IOL)

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

ALCON RESEARCH, LTD. - HUNTINGTON MONARCH IOL DELIVERY SYSTEM, CARTRIDGE; FOLDERS AND INJECTORS, INTRAOCULAR LENS (IOL) Back to Search Results
Model Number ASKU
Device Problem Material Opacification (1426)
Patient Problems Inflammation (1932); Pain (1994); Loss of Vision (2139)
Event Date 09/14/2017
Event Type  Injury  
Manufacturer Narrative
Product evaluation: the product was not returned for analysis.The complaint history and product history records could not be reviewed because the reporting facility did not provide a lot number or any identification traceable to the manufacturing documentation.The product investigation could not identify a root cause for the reported complaint.Not enough information was provided from the account for further investigation.Follow-up information was provided by the surgeon that they do not feel that the cartridges are involved because they are used for non-preloaded monofocal iols and there was no incident with the other iols noticed by him or his colleagues.The manufacturer internal reference number is: (b)(4).
 
Event Description
A doctor reported that eight days following intraocular lens (iol) implantation, the patient presented with inflammation (3+ tyndall).It was noted that there was no change in the usual post-operative treatment.Inflammation had decreased to 1+ tyndall as of (b)(6) 2017 and had not complained of any functional signs.It was noted that the patient¿s other eye was operated on (b)(6) 2017 with a different implant, and there was no inflammation at the eight day postoperative visit.Additional information was received via a company representative, indicating that visual acuity loss and pain were also noted.The patient was treated with dexamethasone with neomycin, triamcinolone, and ofloxacine postoperatively.It was also reported that results were good after one month; however, six patients had posterior capsular opacification (pco) requiring yttrium aluminium garnet (yag) laser treatment at three months, but it is unclear if this patient was affected.The surgeon does not suspect that the cartridge contributed to the event.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
MONARCH IOL DELIVERY SYSTEM, CARTRIDGE
Type of Device
FOLDERS AND INJECTORS, INTRAOCULAR LENS (IOL)
Manufacturer (Section D)
ALCON RESEARCH, LTD. - HUNTINGTON
6065 kyle lane
huntington WV 25702
Manufacturer (Section G)
ALCON RESEARCH, LTD. - HUNTINGTON
6065 kyle lane
huntington WV 25702
Manufacturer Contact
bryan blake
6201 south freeway
mail stop ab2-6
fort worth, TX 76134
8176152230
MDR Report Key7427753
MDR Text Key105370065
Report Number1119421-2018-00409
Device Sequence Number1
Product Code MSS
Combination Product (y/n)N
Reporter Country CodeFR
PMA/PMN Number
P063155
Number of Events Reported1
Summary Report (Y/N)N
Report Source Manufacturer
Source Type foreign,health professional
Reporter Occupation Health Professional
Type of Report Initial
Report Date 04/12/2018
1 Device was Involved in the Event
1 Patient was Involved in the Event
Date FDA Received04/12/2018
Is this an Adverse Event Report? Yes
Is this a Product Problem Report? No
Device Operator Health Professional
Device Model NumberASKU
Device Catalogue NumberASKU
Device Lot NumberASKU
Was Device Available for Evaluation? No
Is the Reporter a Health Professional? Yes
Date Manufacturer Received03/14/2018
Was Device Evaluated by Manufacturer? Device Not Returned to Manufacturer
Is the Device Single Use? Yes
Is This a Reprocessed and Reused Single-Use Device? No
Type of Device Usage Initial
Patient Sequence Number1
Patient Outcome(s) Required Intervention;
Patient Age62 YR
-
-